Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.91
Price to sales ratio
-169.59

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3919
COYA
Coya Therapeutics, Inc. - Common Stock
5.01 USD+3.30%-13.02%+4.81%-18.27%117.52 M USD
3929
FBIO
Fortress Biotech, Inc. - Common Stock
3.62 USD+9.70%+17.53%+24.83%+87.56%120.25 M USD
3942
BDTX
Black Diamond Therapeutics, Inc. - Common Stock
1.89 USD-0.53%-10.85%+5.00%-35.93%108.30 M USD
3949
NTHI
NeOnc Technologies Holdings, Inc. - Common Stock
3.90 USD-9.72%-10.76%-18.75%-55.50%101.45 M USD

Frequently asked questions about Oncolytics Biotech Inc. - Common Stock

What is the Oncolytics Biotech Inc. - Common Stock stock price today?

The current price of Oncolytics Biotech Inc. - Common Stock (ONCY) is 0.93. Over the past 24 hours, the stock has changed by 0.00%. Follow the ONCY chart for real-time price dynamics.

What is the stock ticker of Oncolytics Biotech Inc. - Common Stock?

Oncolytics Biotech Inc. - Common Stock trades under the ticker ONCY. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Oncolytics Biotech Inc. - Common Stock stock going up?

ONCY has changed by +9.41% over the last week, +13.41% over the last month, and -22.50% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Oncolytics Biotech Inc. - Common Stock net income for the last quarter?

Oncolytics Biotech Inc. - Common Stock reported net income of -9.24 M for the last quarter. The previous quarter showed -23.67 M, which means net income changed by +60.95%.

How many employees does Oncolytics Biotech Inc. - Common Stock have?

As of the latest available data, Oncolytics Biotech Inc. - Common Stock has 29 employees. Workforce size can provide additional context about the company's scale and operations.

What is Oncolytics Biotech Inc. - Common Stock EBITDA?

Oncolytics Biotech Inc. - Common Stock EBITDA is -9.27 M, and its EBITDA margin is 154.52 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Oncolytics Biotech Inc. - Common Stock stock?

You can buy Oncolytics Biotech Inc. - Common Stock (ONCY) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Oncolytics Biotech Inc. - Common Stock stock?

Investing in Oncolytics Biotech Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ONCY chart and related analysis on metatrader.com as part of your research.

Oncolytics Biotech Inc. - Common Stock

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

News